Literature DB >> 8835820

Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions.

H Matsuda1, N Konishi, Y Hiasa, I Hayashi, T Tsuzuki, M Tao, Y Kitahori, N Yoshioka, T Kirita, M Sugimura.   

Abstract

Exons 1-3 of the p16/CDKN2 gene, exons 4-9 of the p53 gene and exons 1 and 2 of H-, K- and N-ras genes were screened for mutations by a combination of immunohistochemistry and single-strand conformational polymorphism (SSCP) analyses of polymerase chain reaction products from human surgical samples of both frank oral squamous cell carcinomas and premalignant lesions. The samples included 20 squamous cell carcinomas, 10 epithelial dysplasias and 10 epithelial hyperplasias. No identifiable gene mutations were detected in any of the dysplasias or hyperplasias, while 2 (10%) deletions and 2 (10%) mutations of p16/CDKN2, along with 5 (25%) p53 mutations were found in the advanced carcinomas, yielding characteristic p16/ CDKN2 and p53 changes. A mutation in the K-ras gene was found in single carcinoma and dysplastic samples. From the data, it can be argued that p16/CDKN2 and p53 mutations are relatively late occurrences in human oral tumorigenesis and that genetic alterations of the ras genes may not play a significant role in squamous neoplasia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835820     DOI: 10.1111/j.1600-0714.1996.tb01377.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

1.  Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis.

Authors:  Eleftherios Vairaktaris; Georgios Papageorgiou; Spyridoula Derka; Panagiota Moulavassili; Emeka Nkenke; Peter Kessler; Stavros Vassiliou; Veronica Papakosta; Sofia Spyridonidou; Antonis Vylliotis; Andreas C Lazaris; Sofia Anagnostopoulou; Constantinos Mourouzis; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

2.  Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity.

Authors:  R C Jordan; G Bradley; J Slingerland
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

4.  Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients.

Authors:  Anusri Tripathi Bhar; Soma Banerjee; Neelanjana Chunder; Anup Roy; Arunava Sengupta; Bidyut Roy; Susanta Roychowdhury; Chinmay Kumar Panda
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-03       Impact factor: 4.553

5.  Immunohistochemical characterization of cyclin dependent kinase-4 in different histological grades of oral leukoplakia and oral squamous cell carcinoma.

Authors:  Ndvn Shyam; Nirmala N Rao; Raman Ds Narang; Jiji George; Sanjay R Bommu; G Kiran
Journal:  J Oral Maxillofac Pathol       Date:  2014-01

6.  Integrative analysis of genomic and transcriptomic data of normal, tumour, and co-occurring leukoplakia tissue triads drawn from patients with gingivobuccal oral cancer identifies signatures of tumour initiation and progression.

Authors:  Arnab Ghosh; Chitrarpita Das; Sandip Ghose; Arindam Maitra; Bidyut Roy; Partha P Majumder; Nidhan K Biswas
Journal:  J Pathol       Date:  2022-04-21       Impact factor: 9.883

7.  C-deletion in exon 4 codon 63 of p53 gene as a molecular marker for oral squamous cell carcinoma: A preliminary study.

Authors:  Hemani Sukhija; Rajkumar Krishnan; N Balachander; Karthik Raghavendhar; Ramya Ramadoss; Sukanta Sen
Journal:  Contemp Clin Dent       Date:  2015-09

8.  Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.

Authors:  Megan L Ludwig; Andrew C Birkeland; Rebecca Hoesli; Paul Swiecicki; Matthew E Spector; J Chad Brenner
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.